Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Kira Says First-in-Human Trial Shows Complement Candidate Effective

publication date: Nov 3, 2022

Kira Pharmaceuticals, a Boston-Suzhou biotech, presented positive first-in-human data from a Phase I trial of its bifunctional therapy that targets the alternative and terminal complement pathways. In the trial, KP104 produced dose-dependent inhibition of the alternative pathway and terminal pathway of complement activation, according to biomarker data. One month ago, Kira was approved to start Phase II trials of KP104 in patients with lupus in the US, China and Australia. Kira focuses on complement-based therapies to treat immune-mediated disease. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital